151 related articles for article (PubMed ID: 22701038)
1. Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas.
Nakano K; Takahashi S; Yuasa T; Nishimura N; Mishima Y; Sakajiri S; Yokoyama M; Tsuyama N; Ishikawa Y; Hatake K
Jpn J Clin Oncol; 2012 Aug; 42(8):697-703. PubMed ID: 22701038
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus.
Okuma HS; Iwasa S; Shoji H; Takashima A; Okita N; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y
Anticancer Res; 2014 Sep; 34(9):5037-41. PubMed ID: 25202088
[TBL] [Abstract][Full Text] [Related]
3. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer).
Kenmotsu H; Niho S; Ito T; Ishikawa Y; Noguchi M; Tada H; Sekine I; Watanabe S; Yoshimura M; Yamamoto N; Oshita F; Kubota K; Nagai K
Lung Cancer; 2014 Jun; 84(3):254-8. PubMed ID: 24679951
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
Niho S; Kenmotsu H; Sekine I; Ishii G; Ishikawa Y; Noguchi M; Oshita F; Watanabe S; Nakajima R; Tada H; Nagai K
J Thorac Oncol; 2013 Jul; 8(7):980-4. PubMed ID: 23774385
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas.
Lu ZH; Li J; Lu M; Zhang XT; Li J; Zhou J; Wang XC; Gong JF; Gao J; Li Y; Shen L
Med Oncol; 2013; 30(3):664. PubMed ID: 23864251
[TBL] [Abstract][Full Text] [Related]
7. Activity of a three-drug combination including cisplatin (CLOVER regimen) for poorly differentiated neuroendocrine carcinoma.
Bajetta E; Catena L; Biondani P; Pusceddu S; Valente M; Bianco N; Novelli E
Anticancer Res; 2014 Oct; 34(10):5657-60. PubMed ID: 25275070
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma.
Okita NT; Kato K; Takahari D; Hirashima Y; Nakajima TE; Matsubara J; Hamaguchi T; Yamada Y; Shimada Y; Taniguchi H; Shirao K
Gastric Cancer; 2011 Jun; 14(2):161-5. PubMed ID: 21327441
[TBL] [Abstract][Full Text] [Related]
9. Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung.
Fujiwara Y; Sekine I; Tsuta K; Ohe Y; Kunitoh H; Yamamoto N; Nokihara H; Yamada K; Tamura T
Jpn J Clin Oncol; 2007 Jul; 37(7):482-6. PubMed ID: 17652109
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer.
Kim HG; Lee GW; Kang JH; Kang MH; Hwang IG; Kim SH; Hahm JR; Jeong YY; Kim HC; Lee JD; Lee JS; Hwang YS
Lung Cancer; 2008 Aug; 61(2):220-6. PubMed ID: 18272249
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of a 3-week schedule of irinotecan combined with cisplatin in previously untreated extensive-stage small-cell lung cancer.
Lee JE; Park HS; Jung SS; Kim JO; Kim SY
Oncology; 2007; 73(1-2):76-80. PubMed ID: 18334853
[TBL] [Abstract][Full Text] [Related]
12. [A case of poorly-differentiated neuroendocrine carcinoma of the ascending colon with multiple liver metastases successfully treated with cisplatin and irinotecan].
Yamashita K; Ishikawa D; Nanjo S; Takeuchi S; Yamada T; Mouri H; Ohtsubo K; Yasumoto K; Kumagai M; Ueda Y; Yano S
Gan To Kagaku Ryoho; 2012 Sep; 39(9):1427-30. PubMed ID: 22996784
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.
Hainsworth JD; Spigel DR; Litchy S; Greco FA
J Clin Oncol; 2006 Aug; 24(22):3548-54. PubMed ID: 16877720
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity.
Okuma Y; Hosomi Y; Takagi Y; Iguchi M; Okamura T; Shibuya M
Lung Cancer; 2011 Dec; 74(3):492-6. PubMed ID: 21665316
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.
Kulke MH; Wu B; Ryan DP; Enzinger PC; Zhu AX; Clark JW; Earle CC; Michelini A; Fuchs CS
Dig Dis Sci; 2006 Jun; 51(6):1033-8. PubMed ID: 16865563
[TBL] [Abstract][Full Text] [Related]
16. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Welin S; Sorbye H; Sebjornsen S; Knappskog S; Busch C; Oberg K
Cancer; 2011 Oct; 117(20):4617-22. PubMed ID: 21456005
[TBL] [Abstract][Full Text] [Related]
17. A Phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206).
Eba J; Kenmotsu H; Tsuboi M; Niho S; Katayama H; Shibata T; Watanabe S; Yamamoto N; Tamura T; Asamura H; ;
Jpn J Clin Oncol; 2014 Apr; 44(4):379-82. PubMed ID: 24474818
[TBL] [Abstract][Full Text] [Related]
18. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
Kubota K; Hida T; Ishikura S; Mizusawa J; Nishio M; Kawahara M; Yokoyama A; Imamura F; Takeda K; Negoro S; Harada M; Okamoto H; Yamamoto N; Shinkai T; Sakai H; Matsui K; Nakagawa K; Shibata T; Saijo N; Tamura T;
Lancet Oncol; 2014 Jan; 15(1):106-13. PubMed ID: 24309370
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer.
Han JY; Lim KY; Yu SY; Yun T; Kim HT; Lee JS
Cancer; 2011 May; 117(10):2178-85. PubMed ID: 21523731
[TBL] [Abstract][Full Text] [Related]
20. Nedaplatin and irinotecan in patients with large-cell neuroendocrine carcinoma of the lung.
Kenmotsu Y; Oshita F; Sugiura M; Murakami S; Kondo T; Saito H; Yamada K
Anticancer Res; 2012 Apr; 32(4):1453-6. PubMed ID: 22493385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
